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Objectives. High mobility group box 1 (HMGB1) is a nuclear protein that acts 
as an alarmin when released into the extracellular milieu. HMGB1 is a 
biomarker of active disease in several systemic autoimmune diseases. 
Behçet’s disease (BD) is a systemic inflammatory disorder with a 
waxing/waning course. The objective of this study is to evaluate serum 
HMGB1 levels as a possible biomarker for disease activity in BD.  
Methods. A cross-sectional study was performed in 26 BD patients and 20 
healthy controls measuring serum HMGB1 levels. The Brazilian version of the 
simplified Behçet’s Disease Current Activity Form (BR-BDCAFs) was used to 
measure disease activity.  
Results. Serum HMGB1 levels were higher in patients with active disease 
[3.82 (2.54-6.11)ng/ml], in patients with BD without active disease but still on 
therapy [2.76 (1.89-5.78)ng/ml] and in patients in remission without treatment 
[2.66 (1.86-4.70)ng/ml] than in healthy controls [0.96 (0.59-1.39)ng/ml], p < 
0.001. Levels were comparable between BD patients with active disease, BD 
without active disease but still on therapy and those in remission without 
treatment (p = 0.432). There was no correlation between serum HMGB1 
levels and BR-BDCAFs (Rho = 0.195; p = 0.339). No association could be 
found between serum HMGB1 levels and specific disease involvement or 
therapy. So, serum HMGB1 levels cannot be used as a biomarker in BD.   
Conclusion. Serum HMGB1 levels are increased in patients with BD as 
compared to healthy controls. However, no association was found with 




Behçet’s disease (BD) is a chronic multisystemic inflammatory disease 
of unknown etiology classified as a systemic vasculitis. It is characterized by 
recurrent attacks of oral ulcers, genital ulcers, cutaneous lesions, eye 
inflammation, and the occurrence of articular, neurological, vascular and 
intestinal manifestations [1]. Although BD is reported to occur all over the 
world, its prevalence is higher in countries along the ancient Silk Road. The 
etiology of BD is unknown and it is believed that environmental factors play a 
role in genetically predisposed individuals. HLA-B51 is the most important 
genetic marker associated with BD, especially in Turkish and Asian 
populations from the Middle East to the Far East whereas the association 
between BD and HLA-B51 is weaker in Caucasians [1,2]. 
Innate immunity plays an important role in the pathophysiology of BD 
with the participation of γδ T cells, NK cells, and neutrophils. γδ T cells are 
involved in the protection of mucosa and skin against invading organisms. 
Increased numbers of γδ T cells are found in mucosal lesions and in 
peripheral blood of BD patients. These cells express activation markers (e.g. 
CD29 and CD69) and produce inflammatory cytokines such as interferon 
(IFN)γ, tumor necrosis factor (TNF)α, and interleukin(IL)-8 [3,4]. Activated NK 
cells have been shown to be increased in peripheral blood of patients with 
active BD [7]. Neutrophils are hyperactive and contribute to tissue injury in BD 
with increased chemotaxis, phagocytosis, myeloperoxidase expression and 
production of reactive oxygen species (ROS) [3]. Cytokines and chemokines 
secreted by antigen presenting cells and T cells have been suggested to 
cause abnormal neutrophil activation in BD [4].  
High mobility group box-1 (HMGB1) is a non-histone nuclear protein 
that contributes to chromatin architecture and regulates transcription. HMGB1 
may be passively released by necrotic cells or actively secreted by activated 
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cells [5]. Once outside the cell, HMGB1 acts as an alarmin or a danger 
associated molecular pattern (DAMP) binding to receptors and sensors of 
innate immunity such as the receptor for advanced glycation end-products 
(RAGE) and Toll-like receptor (TLR)-2, TLR-4, and TLR-9. Extra-cellular 
HMGB1 triggers inflammatory reactions mainly by inducing cytokine secretion 
and chemotaxis [6].  
An association between increased serum HMGB1 levels and disease 
activity has been described in several systemic autoimmune diseases such as 
systemic lupus erythematosus, juvenile idiopathic arthritis, rheumatoid 
arthritis, primary Sjögren’s syndrome, systemic sclerosis and in ANCA-
associated vasculitis [5-8]. Recently, a study performed in Korea found an 
association between higher serum HMGB1 levels and intestinal involvement 
in BD [9]. Gastrointestinal involvement of BD is commonly described in 
patients from the Far East, being observed in one third of BD patients from 
Japan [10]. However, intestinal involvement in BD is extremely rare in BD 
patients from other countries, including Brazil where this manifestation is 
found in only 3.3-6.6% of cases [10,11]. In this study we evaluated serum 
HMGB1 levels in patients with BD in order to assess associations with 
disease activity and specific disease manifestations in a Brazilian population 
of BD patients.     
 
Patients and methods 
Study population 
Twenty-six consecutive patients with BD and 20 age (39.0 ± 11.5 
years vs. 38.5 ± 13.5 years; p = 0.888) and sex (65.4% vs. 90.0% females; p 
= 0.082) matched healthy controls were included in this cross-sectional study. 
BD patients were under regular follow-up at the Vasculitis Outpatient Clinic at 
Universidade Federal de São Paulo (Unifesp). Inclusion criteria included age 
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above 18 years and fulfillment of the International Study Group diagnostic 
criteria for BD [12]. Disease activity of BD was evaluated with the Brazilian 
version of the simplified Behçet’s Disease Current Activity Form (BR-
BDCAFs) [13]. Active disease was considered if BR-BDCAF(s) was equal to 
or greater than 2, patients with a BR-BDCAF(s) score equal to zero were 
divided in two groups: BD without still on therapy and BD patients without 
treatment. Thirteen BD patients presented active disease, 10 BD patients 
were without active disease but still on therapy and 3 BD patients were in 
remission without treatment. All patients gave informed written consent 
according to the Declaration of Helsinki and the study was approved by the 
institutional ethics committee.  
Information about previous and current BD manifestations and about 
current therapy was retrieved from medical charts. The BR-BDCAF(s) was 
recorded at each visit, and comprehended scoring for oral ulcers, genital 
ulcers, cutaneous lesions (i.e. erythema nodosum-like and acne-like lesions), 
joint complaints, eye involvement (i.e. uveitis and/or retinal vasculitis), neuro-
BD, vasculo-BD (i.e. venous thrombosis and/or arterial aneurysms), and 
intestinal involvement. Eye disease, neuro-BD and vasculo-BD were 
considered major organ involvement of BD.  
 
Serum HMGB1 
          Serum HMGB1 levels were determined by enzyme-linked 
immunosorbent assay (ELISA) using a commercial kit (Shino Test, 
Sagamihara, Kanagawa, Japan) according to the manufacturer’s instructions. 






Statistical analysis was performed using SPSS software version 20.0 
and graphs were created with Graph Pad Prism version 3.02. Mean ± 
standard deviation or median and interquartile range were used to present 
continuous variables as appropriate. Categorical variables were presented as 
total number and percentage. Continuous parameters were analyzed using 
Student’s t test, Mann-Whitney U test or by Kruskal-Wallis test and 
categorical variables were analyzed using Chi-square test or Fisher’s exact 
test. Correlations between numerical data were performed with Spearman’s 
correlation coefficient. The significance inference level was established at 5% 
(p < 0.05). 
 
Results  
Table 1 depicts clinical features and current therapy of BD patients. 
Half of the patients were using immunosuppressive therapy and only one 
patient was treated with anti-TNFα agents. Five BD patients (19.2%) had only 
mucocutaneous involvement and joint complaints, whereas the remaining 21 
BD patients had at least one actual or previous major involvement of BD (i.e. 




Table 1 – Disease features and therapy of 26 patients with Behçet’s disease 
at the time of the study. 
Variables Results 
Age at disease onset, years 30.5 ± 10.8 
Disease duration, years 8.5 (2.7-12.0) 
Active disease, n (%) 13 (50.0) 
BR-BDCAFs 2.0 (2.0-2.5) 
Disease manifestations at study  
   Oral ulcers, n (%) 7 (26.9) 
   Genital ulcers, n (%) 6 (23.1) 
   Cutaneous involvement, n (%) 2 (7.7) 
   Eye involvement, n (%) 5 (19.2) 
   Neuro-BD, n (%) 3 (11.5) 
Disease manifestations ever presented by BD patients  
   Oral ulcers, n (%) 26 (100.0) 
   Genital ulcers, n (%) 23 (88.5) 
   Cutaneous manifestations, n (%) 22 (84.5) 
   Eye involvement, n (%) 18 (69.2) 
   Arthralgias or arthritis, n (%) 12 (46.2) 
   Neuro-BD, n (%) 6 (23.1) 
   Vasculo-BD, n (%) 4 (15.4) 
Therapy  
   Colchicine, n (%) 9 (34.6) 
   Colchicine + benzathine penicillin, n (%) 4 (15.4) 
   Thalidomide, n (%) 4 (15.4) 
   Prednisone, n (%) 10 (38.5) 
   Azathioprine, n (%) 11 (42.3) 
   Cyclosporine A, n (%) 2 (7.7) 
   Methotrexate, n (%) 1 (3.8) 
   Cyclophosphamide, n (%) 1 (3.8) 
   Infliximab, n (%) 1 (3.8) 
No therapy, n (%) 3 (11.5) 
Continuous data are presented as mean ± standard deviation or as median and interquartile 
range; BD – Behçet’s disease; BR-BDCAFs – simplified Behçet’s Disease Current Activity 




Serum HMGB1 levels were significantly higher in BD patients as 
compared to healthy controls [2.86 (2.32-5.27)ng/ml vs. 0.96 (0.59-
1.39)ng/ml; p < 0.0001]. Also, no significant differences were found in serum 
HMGB1 levels among BD patients with active disease, BD patients without 
active disease but still on therapy and those in remission without treatment 
[3.82 (2.54-6.11)ng/ml vs. 2.76 (1.89-5.78)ng/ml vs. 2.64 (1.72-2.86)ng/ml; p 
= 0.432]. Serum HMGB1 levels were significantly higher in all BD subgroups 
compared with healthy controls (Figure 1). There was no correlation between 
serum HMGB1 levels and BR-BDCAFs score (Rho = 0.195; p = 0.339) or 
disease duration (Rho = 0.010; p = 0.962). 
 
Figure 1 – Serum HMGB1 levels in patients with Behçet’s disease with active 
disease, BD in remission while on therapy or BD in remission without 
treatment and healthy controls. 
 
Median serum HMGB1 levels are significantly higher in BD patients with active disease, BD in 
remission but still on therapy and BD in remission without treatment than in healthy controls (p 




Within the group of thirteen BD patients with active disease at the time 
of the study, no difference could be found in serum HMGB1 levels between 
the eight patients with major organ involvement (i.e. five presenting eye 
disease and three with neuro-BD) and the five patients with only 
mucocutaneous disease [3.82 (2.28-5.50)ng/ml vs. 2.67 (2.54-7.48)ng/ml; p = 
0.909].  
Finally, serum HMGB1 levels did not differ between BD patients with 
and without prednisone [2.86 (1.65-4.94)ng/mL vs. 2.92 (2.45-6.09)ng/mL; p = 
0.598] or between BD patients with and without azathioprine [3.18 (2.57-
5.10)ng/mL vs. 2.67 (2.01-5.79)ng/mL; p = 0.815]. Amongst BD patients on 
prednisone, serum HMGB1 levels were similar between patients with a high 
daily dose (i.e. >20mg/day) and those with a low daily dose (i.e. <10mg/day) 
[3.83 (2.28-5.22)ng/ml vs. 2.64 (1.22-6.41)ng/ml; p = 0.251].    
 
Discussion 
In this study, we observed higher serum HMGB1 levels in BD patients 
than in healthy controls. All BD subgroups including patients with active 
disease, patients without active disease but still on therapy and patients in 
remission without treatment, presented significantly higher serum HMGB1 
levels than healthy controls. Although, serum HMGB1 levels were higher in 
patients with active disease than in patients without active disease (with or 
without therapy), the difference was not significant. No correlation could be 
found between serum HMGB1 levels and disease activity measured by BR-
BDCAFs. No association could be found with individual BD manifestations or 
with major disease involvement such as neuro-BD, eye inflammation and 
vasculo-BD. Furthermore, there was no association between prednisone or 
immunosuppressant use and serum HMGB1 levels. 
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Neutrophils are important effector cells in the pathogenesis of BD 
contributing to tissue damage and disease manifestations [3,4]. There is 
evidence that extracellular HMGB1 exerts several effects on neutrophils. In 
vitro studies have shown that binding of HMGB1 to TLR4 activates 
neutrophils leading to nuclear translocation of NFκB. In addition, HMGB1 
induces the production of cytokines such as TNFα and IL-8, and the activation 
of NADPH oxidase resulting in ROS production and increase of Mac-1-
mediated adhesive and migratory functions of phagocytes [14-17]. Moreover, 
HMGB1 also induces the formation of neutrophil extracellular traps (NET) 
through interactions with TLR4 as well [18]. Thus, the observation of elevated 
serum HMGB1 levels in BD patients might indicate a possible role of 
extracellular HMGB1 as a mediator of neutrophil activation in BD.  
A previous study evaluated HMGB1 levels in Korean patients with BD. 
Similarly to our study, BD patients had significantly higher serum HMGB1 
levels than healthy controls and no difference could be found between 
patients with active disease and remission. Patients with gastrointestinal 
involvement presented the highest HMGB1 serum levels, whereas no 
association could be found with any other manifestation of BD [9]. The 
association between higher serum HMGB1 levels and intestinal involvement 
in BD seems reasonable, since gastrointestinal involvement may be extensive 
and is characterized by deep ulcerations involving any segment of the 
gastrointestinal tract [1,2].      
The lack of association between serum HMGB1 levels and specific 
disease manifestations in the present study may be due to the relatively low 
disease activity in BD patients evaluated in this study and the absence of BD 
patients with active gastrointestinal involvement. Vascular and neurological 
involvements of BD are severe disease manifestations that have an impact on 
prognosis of BD patients [1,2]. Amongst the 13 BD patients with active 
disease enrolled in this study only three had active neuro-BD at the time of 
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evaluation while the remaining patients presented either ocular or 
mucocutaneous disease which may not be associated with intense systemic 
inflammatory reactions. Therefore, evaluation of a higher number of patients 
with severe BD manifestations would help to clarify this issue. Although 
neurological involvement may be found in up to one third of BD patients in 
Brazil, it might be difficult to enroll patients at the onset of neuro-BD [11]. We 
could not find any association between serum HMGB1 levels and specific 
disease manifestations in BD including severe disease involvement (i.e. 
neuro-BD, eye disease and vasculo-BD), since BD has a relapsing-remitting 
course and most of these patients were in remission at the time of the study.          
We also could not find associations between therapy and serum 
HMGB1 levels. Patients on prednisone or on azathioprine presented similar 
HMGB1 levels compared to those without those agents. Reduced serum 
HMGB1 levels have been described in patients on statins or prednisone [19]. 
However, this effect has not been observed with immunosuppressive agents 
[20]. Limitations of the present study include the relatively small number of BD 
patients and the cross-sectional nature of this survey. The lack of longitudinal 
data makes it difficult to draw definite conclusions about associations between 
serum HMGB1 levels and disease activity as well as expression of particular 
manifestations of BD. 
In conclusion, serum HMGB1 levels were shown to be increased in 
patients with BD. However, no association could be found between serum 








• BD is associated with increased serum HMGB1 levels in comparison to 
healthy controls. 
• No association was found between circulating HMGB1 and disease 
activity or specific manifestations in BD. 
• No association was observed between prednisone or azathioprine use 
and serum HMGB1 levels. 
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